Vincristine is a chemotherapic medication used to treat a variety of cancers, including acute lymphocytic leukemia, acute myeloid leukemia, Hodgkin's disease, neuroblastoma, and small cell lung cancer. Suppliers market it in the form of an intravenous solution.
The drug was developed and first introduced to the market in 1963 and initially marketed by supplier Eli Lilly. Since then, other manufacturing companies, such as Teva, Pfizer, and Gedeon Richter have joined the market with their vincristine formulations. As of now, the medication is available in both generic and trade name forms and the World Health Organization has included it in its list of Essential Medicines needed for a basic health system.
Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.
1ml unit of 1mg/ml vincristine solution costs approximately 8.00 EUR.